| Name | Title | Contact Details |
|---|
California Marine Diesel is a Long Beach, CA-based company in the Business Services sector.
Chaisson Chaisson is a Destrehan, LA-based company in the Business Services sector.
South Pole is a Swiss-based climate consultancy and carbon finance leader, founded in 2006 and headquartered in Zurich. The company employs over 800 people across more than 20 countries, focusing on helping organizations achieve net-zero emissions. South Poles mission is to create significant climate impact by channeling finance into sustainable projects and aligning climate action with business growth. The company offers a range of services, including climate strategy advisory, carbon offsetting solutions, and support for sustainable supply chains. South Pole develops and manages over 850 certified climate projects globally, focusing on renewable energy, forestry, and community initiatives. They also provide climate finance tools and risk management services to ensure compliance and integrity in carbon markets. With a client base of over 1,000 organizations, including Fortune 500 companies and governments, South Pole emphasizes ecosystem health, job creation, and community resilience in its projects.
Destination Bride Llc is a Chatham, NY-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.